Table 2. Correlation of plasma miRNA33b/16 (A) or miRNA33b (B) levels and clinical parameters in patients with T2DM.
| A. miRNA33b/16 | B. miRNA33b | ||||
|---|---|---|---|---|---|
| r | p value | r | p value | ||
| BMI | 0.194 | 0.177 | BMI | 0.112 | 0.441 |
| FBS | 0.059 | 0.682 | FBS | −0.133 | 0.356 |
| HbA1c | −0.032 | 0.828 | HbA1c | −0.095 | 0.51 |
| IRI | 0.326 | 0.021 | IRI | 0.263 | 0.065 |
| s-CPR | 0.28 | 0.049 | s-CPR | 0.237 | 0.098 |
| u-CPR | −0.049 | 0.733 | u-CPR | 0.098 | 0.499 |
| LDL-C | 0.163 | 0.259 | LDL-C | −0.09 | 0.533 |
| TG | 0.351 | 0.012 | TG | 0.086 | 0.545 |
| LDL-C/HDL-C | 0.241 | 0.091 | LDL-C/HDL-C | 0.059 | 0.687 |
| HDL-C | −0.21 | 0.143 | HDL-C | −0.197 | 0.171 |
| ApoA-I | −0.169 | 0.241 | ApoA-I | −0.245 | 0.086 |
Plasma miRNA33b/16 levels revealed a positive relationship with IRI or with s-CPR (A). Plasma miRNA33b/16 levels also demonstrated a positive correlation with TG and showed a negative tendency with HDL-C (A). Similar tendencies between miRNA33b levels (relative to total RNA) and the above-mentioned clinical parameters were revealed; however, statistically significant differences were not seen (B). Statistical significance was defined as P < 0.05.